Key result
Rapid reverse-phase HPLC assay quantifies serum amiodarone with ~97% accuracy.
A rapid and reliable HPLC assay was developed for the accurate measurement of the antiarrhythmic drug amiodarone and its metabolite in serum.
Answers are grounded in this paper and cite their sources.
May support amiodarone therapeutic monitoring; leaves open prospective outcome validation.
A rapid and reliable high-performance liquid chromatographic (HPLC) assay has been developed for the measurement of the antiarrhythmic drug, amiodarone (A), and its metabolite, N-desethyl-amiodarone (NDA), in serum. The procedure involves addition of absolute ethanol to serum, previously adjusted to pH 6, followed by centrifugation. The supernatant is analyzed by reverse-phase HPLC with ultraviolet-visible detection. There is no intereference from endogenous substances or other commonly used antiarrhythmic agents. The mean overall accuracy of the HPLC assay is 96.9 +/- 9.1 (SD)% (n = 37) for A over the concentration range 0.10-10.00 micrograms/mL, and 99.8 +/- 4.8 (SD)% (n = 32) for NDA over the concentration range 0.10-7.50 micrograms/mL. The within-day coefficient of variation is less than 7% for A and NDA. The lower limit of quantitative sensitivity is 0.10 micrograms/mL for A and NDA, and the lower limit of qualitative detection is 1.0 ng for both compounds.
No takes yet. Share an insight, caveat, or question.
Brien et al. (1983) studied this question. High-performance liquid chromatographic (HPLC) assay was evaluated on Assay accuracy and sensitivity. A rapid reverse-phase HPLC assay accurately measured amiodarone and N-desethyl-amiodarone in serum with a quantitative sensitivity limit of 0.10 micrograms/mL.
Synapse has enriched 10 related papers. Consider them for comparative context: